Wed, Aug 27, 2014, 5:35 AM EDT - U.S. Markets open in 3 hrs 55 mins


% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • rojospan rojospan Nov 24, 2012 9:12 PM Flag

    HCV pill race

    Very competitive field and I am not sure that it will generate 30 billion dollar market. GILD and ABT will face the same issue like MRK and VRTX due to Hep C patients entering into drug trial and getting the oral therapy for free.
    I don't know at what viral load patients stop transmitting Hep C virus, if they do? I don't see any drug company working on Hep C prophylaxsis at present time.

    I am hoping VX 222 will reproduce 85% or better SVR 12 with Telaprevir and Ribavirin and I hope to see VRTX advancing this twice daily regimen into phase III as rapidly, as they could ( SVR 12 is 99 % representation of SVR 24). I hope Virochem 350 million buyout will bring some reward back.With Affordable healthcare act, I see significant value in relatively low cost therapy even if it is not a single pill or a once daily dose.
    Even if the drug only work for non cirrhotic treatment naive group, it is worth a shot. Only 10% patient are treatment resistant and VRTX can leave GILD and ABT to have that market share with their 11 billion ( plus additional development cost) market drug investments.

93.64+1.88(+2.05%)Aug 26 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.